AU2014254016B2 - Peptide compounds and methods of production and use thereof - Google Patents

Peptide compounds and methods of production and use thereof Download PDF

Info

Publication number
AU2014254016B2
AU2014254016B2 AU2014254016A AU2014254016A AU2014254016B2 AU 2014254016 B2 AU2014254016 B2 AU 2014254016B2 AU 2014254016 A AU2014254016 A AU 2014254016A AU 2014254016 A AU2014254016 A AU 2014254016A AU 2014254016 B2 AU2014254016 B2 AU 2014254016B2
Authority
AU
Australia
Prior art keywords
arg
ala
gly
phe
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2014254016A
Other languages
English (en)
Other versions
AU2014254016A1 (en
Inventor
Gina L. Griffith
Anne Kasus-Jacobi
H. Anne Pereira
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Oklahoma
Original Assignee
University of Oklahoma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2013/072884 external-priority patent/WO2014089088A1/en
Application filed by University of Oklahoma filed Critical University of Oklahoma
Publication of AU2014254016A1 publication Critical patent/AU2014254016A1/en
Application granted granted Critical
Publication of AU2014254016B2 publication Critical patent/AU2014254016B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1729—Cationic antimicrobial peptides, e.g. defensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
AU2014254016A 2013-04-16 2014-04-16 Peptide compounds and methods of production and use thereof Active AU2014254016B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201361812584P 2013-04-16 2013-04-16
US61/812,584 2013-04-16
US201361813527P 2013-04-18 2013-04-18
US61/813,527 2013-04-18
AUPCT/US2013/072884 2013-12-03
PCT/US2013/072884 WO2014089088A1 (en) 2012-12-03 2013-12-03 Peptide compounds and methods of production and use thereof
PCT/US2014/034392 WO2014172474A2 (en) 2013-04-16 2014-04-16 Peptide compounds and methods of production and use thereof

Publications (2)

Publication Number Publication Date
AU2014254016A1 AU2014254016A1 (en) 2015-11-05
AU2014254016B2 true AU2014254016B2 (en) 2018-02-22

Family

ID=51731978

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014254016A Active AU2014254016B2 (en) 2013-04-16 2014-04-16 Peptide compounds and methods of production and use thereof

Country Status (7)

Country Link
US (3) US9624283B2 (cg-RX-API-DMAC7.html)
EP (1) EP2986309B1 (cg-RX-API-DMAC7.html)
JP (1) JP6405365B2 (cg-RX-API-DMAC7.html)
AU (1) AU2014254016B2 (cg-RX-API-DMAC7.html)
CA (1) CA2908693C (cg-RX-API-DMAC7.html)
DK (1) DK2986309T3 (cg-RX-API-DMAC7.html)
WO (1) WO2014172474A2 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3802568A4 (en) 2018-06-08 2022-07-13 The Board of Regents of the University of Oklahoma PEPTIDE THERAPEUTICS USED TO TREAT ALZHEIMER'S DISEASE AND RELATED DISEASES
JP2025016812A (ja) * 2021-12-16 2025-02-05 レグセル株式会社 免疫系の異常に関連する疾患、障害または症状を処置するための医薬組成物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070135341A1 (en) * 2005-08-01 2007-06-14 Pereira H A Antifungal peptides and methods of use thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5484885A (en) * 1989-07-05 1996-01-16 Emory University Chemotactic, antibiotic and lipopolysaccharide-binding peptide fragments of CAP37
US5627262A (en) 1989-07-05 1997-05-06 The Board Of Regents Of The University Of Oklahoma Method and composition for the treatment of septic shock
US6503881B2 (en) 1996-08-21 2003-01-07 Micrologix Biotech Inc. Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics
US6107460A (en) * 1999-03-01 2000-08-22 The Board Of Regents Of The University Of Oklahoma Antimicrobial peptides and methods of use thereof
US8450071B2 (en) 2002-03-08 2013-05-28 The Board Of Regents Of The University Of Oklahoma Biomarker and method for detecting a chronic inflammatory-associated disease
AU2003220034A1 (en) 2002-03-08 2003-09-22 Heloise, Anne, Pereira, Ph. D. An early detection marker for chronic inflammatory associated diseases
US7655480B2 (en) 2002-03-08 2010-02-02 The Board Of Regents Of The University Of Oklahoma Method for predicting sepsis or an acute infectious inflammatory response
US7354900B2 (en) * 2002-05-03 2008-04-08 The Board Of Regents Of The University Of Oklahoma Treatment and inhibition of ocular infections and wounds by CAP37 and CAP37 peptides
CN101027318B (zh) 2004-07-19 2016-05-25 比奥孔有限公司 胰岛素-低聚物共轭物,制剂及其用途
US9399675B2 (en) 2007-02-28 2016-07-26 The Board Of Regents Of The University Of Oklahoma Methods and compositions for diagnosing Alzheimer's disease and age-related macular degeneration
GB0817121D0 (en) * 2008-09-18 2008-10-29 Univ St Andrews Anti-fungal therapy
WO2011103567A2 (en) 2010-02-22 2011-08-25 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Peptides and methods for inducing cell death
CA2797033C (en) 2010-04-22 2021-10-19 Longevity Biotech, Inc. Highly active polypeptides and methods of making and using the same
US9096679B2 (en) 2012-12-03 2015-08-04 The Board Of Regents Of The University Of Oklahoma Peptide compounds and methods of production and use thereof
US9603896B2 (en) 2012-12-03 2017-03-28 The Board Of Regents Of The University Of Oklahoma Peptide compounds and methods of production and use thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070135341A1 (en) * 2005-08-01 2007-06-14 Pereira H A Antifungal peptides and methods of use thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BACH A. et al., PNAS., 2012, vol. 109, no. 9, pages 3317 - 3322 *
GAULT V. A. et al., BIOCHEMICAL PHARMACOLOGY, 2008, vol. 75, no. 12, pages 2325 - 2333 *
KATO A. et al., BIOPOLYMERS, 2007, vol. 85, no. 1, pages 12 - 18 *
PEREIRA H. A.,CURRENT PHARMACEUTICAL BIOTECHNOLOGY, 2006, vol. 7, no. 4, pages 229 - 234 *

Also Published As

Publication number Publication date
WO2014172474A2 (en) 2014-10-23
CA2908693A1 (en) 2014-10-23
JP6405365B2 (ja) 2018-10-17
DK2986309T3 (en) 2018-05-07
US9624283B2 (en) 2017-04-18
EP2986309A4 (en) 2017-03-08
AU2014254016A1 (en) 2015-11-05
JP2016519109A (ja) 2016-06-30
EP2986309B1 (en) 2018-02-14
US20170073385A1 (en) 2017-03-16
EP2986309A2 (en) 2016-02-24
US20180208633A1 (en) 2018-07-26
CA2908693C (en) 2021-04-06
US20160060315A1 (en) 2016-03-03
WO2014172474A3 (en) 2015-02-19

Similar Documents

Publication Publication Date Title
US20160317617A1 (en) Peptide Compounds and Methods of Production and Use Thereof
US9862748B2 (en) Peptide compounds and methods of production and use thereof
EP3233902B1 (en) Antifibrotic activity of gas6 inhibitor
WO2021237239A1 (en) Active low molecular weight variant of angiotensin converting enzyme 2 (ace2) for the treatment of diseases and conditions of the eye
JP2012512170A (ja) 血管バリア機能の促進および肺線維症の治療する組成物および方法
US20180208633A1 (en) Peptide Compounds and Methods of Production and Use Thereof
JP2016501889A5 (cg-RX-API-DMAC7.html)
WO2010137594A1 (ja) 血管新生誘導活性及び抗菌活性を有するポリペプチドおよびそれを含有する創傷治療剤
JPWO2010061915A1 (ja) 血管新生誘導活性及び抗菌活性を有する新規ポリペプチド並びにその医薬用途
US11884710B2 (en) Peptide compounds and methods of use in wound healing
JP6042106B2 (ja) メチオニン・スルホキシドを含む新規ポリペプチド
AU2006275417B2 (en) Antifungal peptides and methods of use thereof
JP2025503607A (ja) セルピンペプチドおよびその使用方法
KR20250170772A (ko) 이중 알라민 수용체 특이적 표적 펩티드를 포함하는 패혈증 치료용 약학 조성물
HK1244825B (en) Antifibrotic activity of gas6 inhibitor

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)